62

Referencias

Abi-Dargham, A., Rodenhiser, J., Printz, D., et al. (2000). “Increased baseline accupancy of

2D receptors by dopamine in schitzophrenia.” Proc Natl Acad Sci USA, 97, pp. 8104-

8109.

Adolphs, R. (2003). “Cognitive neuroscience of human social behaviour.” Nat Rev

Neurosci, 4, pp. 165-178.

Álvarez, J.R. (1978). Enciclopedia de México, México. vol. XI. Barcelona, Editorial Planeta.

Atkins, M.S., McArthur, A.G., Teske, A.P. (2000). “Ancyromonadida: A New Phylogenetic

Lineage Among the Protozoa Closely Related to the Common Ancestor of

Metazoans, Fungi, and Choanoflagelates (Opisthokonta)”. Journal of Molecular

Evolution, 51, pp. 278-285. Doi: 10. 1007/s002390010089.

Beaulieu, J-M., Ganetdinov, R.R. (2011). “The Physiology, Signaling, and Pharmacology of

Dopamine Receptors”. Pharmacological Reviews, 63(1), pp. 182-217. Doi:

10.1124/pr.110.0022642.

63

Bogenschultz, M.P., Forcehimes, A.A., Pommy, J.A., Wilcox, C.E., Barbosa, P.C.R.

Strassman, R.J. (2015). “Psilocybin-assisted treatment for alcohol dependence: A

proof-of-concept study”. Journal of Psychopharmacology, 29(3), pp. 289-299. Doi:

10.1177/0269881114565144.

Borowiak, K., Machoy-Mokrzynska, A., Majdanik, S., Waloszczyk, P., Piasecka, M., Janus,

T., Jasionowicz-Piatek, E., Parafiniuk, M. (2006). “Psilocin multiple intake resulted

and in cardiotoxic effects”. Acta Toxicologica, 14(1-2), pp. 23-30.

Borowiak, K.S., Ciechanowski, K., Waloszczyk, P. (1998). “Cardiac disorders of young men

in the process of intoxication by a psylocibine from a mushroom species-Psilocybe

semilanceata-A case report.” J Toxicol Clin Toxic, 36, pp. 47-49.

Brody, S., Krause, C., Veit, R., Rau, H. (1998). “Cardiovascular autonomic dysregulation in

users of MDMA (ecstasy).” Psychopharmacology, 136, pp. 390-393.

Canal, C.E., Morgan, D. (2012). “Head-twitch response in rodents induced by the

hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-

evaluation of mechanisms, and its utility as a model.” Drug Test Anal., 4, pp. 556-

576.

Carlson, A. (2001). “A paradigm shift in brain research.” Science, 294, pp.1021-1024.2-

receptors and serotonin release: their role in human platelet aggregation.” Life

Science, 53, pp. 209-215.

Cavalier-Smith, T. (1987). “The origin of Fungi and pseudofungi.” In Rayner A.D.M.,

Brasier, C.M., Moore, D. (eds.). Evolutionary biology of the fungi. Cambridge,

Cambridge University Press.

64

Cavalier-Smith, T. Chao, E.E. (1995). “The opalozoan Apusomonas is related to the common

ancestor of animals, fungi and choanoflagellates.” Proc Roy Soc Lond B Biol Sci, 261,

pp. 1-6.

Cerrito, F., Lazzaro, M., Gaudio, E., Arminio, P., Aloisi, G. (1993). “5-HT

Civelli, O., Bunzow, J.R., Grandy, D.K. (1993). “Molecular diversity of the dopamine

receptors.” Annu Rev Pharmacol Toxicol, 33, pp. 281-307.

Dahlstrom, A., Fuxe, K. (1964). “Evidence for the exisrence of monoamine-containing

neurons in the central nervous system.” Acta Physiologica Scandinavia, 62, pp. 1-55.

Deacon, J. (1980). Fungal Biology. EUA, RU, Blackwell Publishing.

Ehringer H., Hornykiewicz, O. (1960). “Distribution of noradrenaline and dopamine (3-

hydroxytyramine) in the human brain and their behavior in diseases of the

extrapyramidal system.” Klin Wochenschr, 38, pp. 1236-1239. In rhesus monkeys.”

Behav Pharmacol, 15, pp. 149-157.

Fantegrossi, W.E., Woods, J.H., Winger, G. (2004). “Transient reinforcing effects of

phenylisopropylamine and indolealkylamine hallucinogens

Furst, P.T. (1974). “Hallucinogens in pre-Columbian art.” In King, M.E., I.R. Taylor (eds.)

Art and environment in native America. Lubbock, EUA, Texas Tech. University

Press, pp. 55-102.

Ghuran, A., Nolan, J. (2000). “Recreational drug misuse: issues for the cardiologist.” Heart,

83, pp. 627-633.

65

Girgis, R.R., Van Snellenberg, J.X., Glass, A., Kegeles, L.S., Thompson, J.L., Wall, M., Cho,

R.Y., Carter, C.S., Slifstein, M., Abi-Dargham, A., Lieberman, J.A. (2016). “A proof-

of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor

agonist, for cognitive enhancement in schizophrenia”. Journal of

Psychopharmacology, 30(5), pp. 428-435. Doi: 10.1177/0269881116636120.

Goldstein, R.Z., Volkow, N.D. (2011). “Oral methylphenidate normalizes cingulate activity

and decreases impulsivity in cocaine addiction during an emotionally salient

cognitive task.” Neuropsychopharmacology, 36, pp. 366-367.

Griffiths, R.R., Richards, W.A., Johnson, M.W. (2008). “Mystical-type experiences

occasioned by psilocybin mediate attribution of personal meaning and spiritual

significance 14 month later.” J Psychopharmacol, 22, pp. 621-632.

Griffiths, R.R., Bigelow, G.E., Henningfield J.E. (1980). “Similarities in animal and human

drug-taking behavior.” Adv Subst Abuse, 1, pp. 1-90.

Grob, C.S. (2011). “Pilot study of psilocybin treatment for anxiety in patients with advanced-

stage cancer.” Arch Gen Psychiatry, 68, pp. 71-78.

Guzmán, G. (2012). “New taxonomical and ethnomycological observations on psilocybe S.S.

(Fungi, Basidiomycota, Agaricomycetidae, Agaricales, Strophariaceae) from

Mexico, Africa and Spain”. Acta Botanica Mexicana, 100, pp. 79-106.

----------------(2008). “Hallucinogenic Mushrooms in Mexico: An Overview”. Economic

Botany, 62(3), pp. 404-412.

66

----------------(1997). Los nombres de los hongos y lo relacionado con ellos en América

Latina. Xalapa, México, Instituto de Ecología, A.C., Comisión Nacional para el

Conocimiento y Uso de la Biodiversidad.

----------------(1983). “The genus Psilocybe.” Beih. Nova Hedwigia, 74, pp. 1-439.

----------------(1960). Nueva localidad de importancia etnomicológica de los hongos

neurotrópicos mexicanos (Necaxa, Puebla, México). Ciencia (Méx.) 20, pp. 85-87.

Haber, S.N. (2011). “Neuroanatomy of Reward: A View from the Ventral Striatum.” In

Gottfired, J.A. (ed.) Neurobiology of Sensation and Reward. Boca Ratón, Florida,

CRC Press.

Halberstadt, A.L., Geyer, M.A. (2011). “Multiple receptors contribute to the behavioral

effects of indoleamine hallucinogens.” Neuropharmacology, 61, pp. 364-381.

Hassler, F., Bourquin, D., Brennaisen, R., Bär, T., Vollenweider, F.X. (1997).

“Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-

ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man.”

Pharm. Acta Helv., 72, pp. 175-184. Doi: 10.1016/S0031-6865(97)00014-9.

Heim, R. (1957a). “Les agarics hallucinogènes du genre Psilocybe recueillis au cours de notre

récente misión dans le Mexique meridional et central en compagnie de M.R. Gordon

Wasson.” Compt. Rend. Séances Acad. Sci., Paris, 244, pp. 695-700.

--------------(1957b). “Notes préliminaires sur les Agariccs hallucinogènes du Mexique, IV:

Breves latinae diagnoses hallucinogeranum Mexicanarum psicocybarium ad fera

specimina pertinentium.” Rev. Mycol., 22, pp. 58-79.

67

--------------(1956a). “Les champignons divinatoires recueillis par Mme, Valentina Pavlovna

Wasson et M.R. Gordon Wasson au cours des leurs missions de 1954 et 1955 dans

les pays mije, mazatèque, zapotèque et nahua du Mexique meridional el central.

Compt. Rend. Séances Acad. Sci., Paris 242, pp. 1389-1395.

--------------(1956b). “Les Champignons Divinatoires Utilizes dans les Rites del Indies

Mazatèques, Recuellis du Cours de Leur Premier Voyage in Mexique in 1953, par

Mme. Valentina Pavlovna Wasson et M.R. Gordon Wasson.” Comptes Rendus des

Séances de l’Academie de Sciences, 242, pp. 965-969.

Heim, R., Cailleux, R., R. G. Wasson, Théverand, P. (1966). “Nouveilles investigations sur

les champignons hallucinogens.” Arch. Mus. Nat. Hist. Nat., 7(9), pp. 115-218.

Heim, R., R.G. Wasson (1958). “Les champignons hallucinogens du Mexique.” Arch. Mus.

Nat. Hist. Nat., 7(6), pp. 1-322.

Herrera, T., Ulloa, M. (1990). El reino de los hongos. Micología básica y aplicada. México,

Fondo de Cultura Económica.

Hibbert D.S. (2006). “A phylogenetic overview of the Agaricomycotina”. Mycologia, 98(6),

pp. 917-925.

Hilton, B., Cumings, N. (1971). “Asassessment of platelet aggregation induced by 5-

hydroxytryptamine.” Journal of Clinical Pathology, 24, pp. 250-258.

Hintz, W.E.A., Anderson, J.B., Horgen, P.A. (1988). “Nuclear migration and mitochondrial

inheritance in the mushroom Agaricus bitorquis.” Genetics, 119, pp. 35-41.

68

Ishai, A. (2007). “Sex, beauty and the orbitofrontal cortex.” Int J Psychiphysiol, 63, pp. 181-

185.

Johnson, M.W., Garcia-Romeu, Al, Casimano, M.P., Griffiths. R.R. (2014). “Pilot study of

the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction”. Journal of

Psychopharmacology, 28(11), pp. 983-992. Doi: 10.1177/0269881114548296.

Kirk, P.M., Cannon, P.F., David, J.C., Stalpers, J.A. (2001). Ainsworth and Bisby’s

Dictionary of the Fungi. 9th ed. Cambridge, Reino Unido, CAB International

University Press.

Kometer, M., Schmidt, A., Bachmann, R., Struderus, E., Seifritz, E., Vollenweider, F.X.

(2012). “Psilocybin biases facial recognition, goal-directed behavior, and mood state

toward positive relative to negative emotions through different serotonergic

subreceptors.” J Comp Neurol, 493, pp. 479-509.

Laruelle, M., Abi-Dargham, A., van Dyck, C.H., et al. (1996). “Single photon emission

computarized tomography imaging of amphetamine-induced dopamine release in

drug-free schizophrenic subjects.” Proc Natl Acad Sci, 166, pp. 111-113.

Lebedev, A.V., Lövdén, M., Rosenthal, G., Feilding, A., Nutt, D.J., Carhart-Harris, R.

(2015). “Finding the Self by Losing the Self: Neutral Correlates of ego-Dissolution

Under Psilocybin”. Human Brain Mapping, 36, pp. 3137-3153. Doi:

10.1002/hbm.22833.

Leeder, A.C., Palma-Guerrero, J., Glass, N.L. (2011). “Nature Reviews”. Microbiology, 9,

pp. 440-451. Doi: 10.1038/nrmicro2580.

69

León-Portilla, M. (1999). “Pionero de la antropología. Fray Bernardino de Sahagún.”

Arqueología Mexicana, 6(36), pp. 8-13.

Lester, S.J. (2000). “Cardiovascular effects of 3,4-methylenedioxymeth-amphetamine.” Ann

Intern Med, 133, pp. 969-973.

Limanovski, J., Blandenburg, F. (2013). “Minimal self-models and the free energy

principle.” Front Hum Neurosci, 7, p. 547.

Liu, Y., Steenkamp, E.T., Brinkmann, H., Forget, L., Philippe, H., Lang, B.F. (2009).

“Phylogenomic analyses predict sistergroup relationship of nucleariids and Fungi and

paraphyly of zygomycetes with significant support”. MBC Evolutionary Biology,

9(272). Doi: 10.1186/1471-2148-9-272.

Machoy-Mokrzynska, A., Safranov, K., Borowiak, K.S., Majdanik, S., Dziedziejko, V.,

Bialecka,M., et al. (2003). “The influence of psilocin and phenylethylamine on the

energy metabolism in the rat heart.” Acta Toxicologica, 11(1), pp. 13-19.

Maciejczyk, E., Kafarski, P., (2013). “Mannitol in Amanita muscaria-An osmotic blood-

brain barrier disruptor enhancing its hallucinogenic action.” Medical Hypothesis, 81,

pp. 766-767.

Magdalan, J. (2000). “Acute intoxication with hallucinogenic mushrooms.” Adv Clin Exp

Med, 9(1), pp. 91-96.

Mas, M., Farre, M. DelaTorre, L., Roset, P.N., Ortuno, J., Segura, J. et al. (1999).

“Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-

methylenedioxymetamphetamine in humans.” J Pharmacol Exp Therap, 290(1), pp.

136-145.

70

May, G., Taylor, J.W. (1988). “Patterns of mating and mitochondrial DNA inheritance in the

agaric basidiomycete Coprinus cinereus.” Genetics, 118, pp. 213-220.

McIntosh, J. (2016). “¿Qué es la serotonina? ¿Cuál es su función?”. Medical News Today.

Disponible en http://www.medicalnewstoday.com/articles/291259.php.

Missale, C., Nash, S.R., Robinson, S.W., Jaber, M., Caron, M.G. (1998). “Dopamine

receptors: from structure to function.” Physiol Rev, 78, pp. 189-225.

Mitchell, J., Sharp, A. (1964). “Platelet clumping in vitro.” British Journal of Haematology,

10, pp. 78-93.

Mohammad-Zadeh, L.F., Moses, L., Gwaltney-Brant, S.M. (2008). “Serotonin: a review”.

Journal of veterinary Pharmacological Therapy, 31, pp. 187-199. Doi:

10.1111/j.1365-2885.2008.00944x.

Monroe, R.R., Heath, R.G. (1961). “Effects of lysergic acid and various derivatives on depth

and cortical electrograms.” J Neuropsychiatr, 3, pp. 75-82.

Ni, W., Watts, S. (2006). “5-Hydroxytryptamine in the cardiovascular system: focus on the

serotonin transporter (SERT).” Clinical and Experimental Pharmacology and

Physiology, 33, pp. 575-583.

Nieuwenhuis, B.P.S., Debets, A. J. M., Aanen, D.K. (2010). “Sexual selection in mushroom-

forming basidiomycetes”. Proceedings. The Royal Society of Biological Sciences.

Doi:10.1098/rspb.2010.1110.

71

Niznik, H.B., Van Tol, H.H. (1992). “Dopamine receptor genes: new tools for molecular

psychiatry.” J Psychiatry Neurosci, 17, pp. 158-180. And a comparison of their

inhibitors.” Journal of Clinical Pathology, 17, pp. 275-281.

O’Brien, J. (1964). “A comparison of platelet aggregation produced by seven compounds

and a comparison of their inhibitors.” Journal of Clinical Pathology, 17, pp. 275-281.

Passie, T., Seifert, J., Schneider, U., Emrich, H.M. (2002). “The pharmacology of

psilocybin.” Addict. Biol. 7, 357-364. Doi: 10.1371/journal.pone.0009019.

Patterson, D.J. (1999). “The diversity of eukaryotes. Am Nat, 154 (suppl), pp. S96-S124.

Pavlovna Wasson, V., Wasson, G. (1957). Mushrooms. Russia and History, vol II. Nueva

York, Pantheon Books.

Poling, A., Bryceland, J. (1979). “Voluntary drug self-administration by nonhumans: A

review.” J Psychoactive Drugs, 11, pp.185-190.

Quasim, A., Towned, J., Davies, M.K. (2001). Ecstasy induced acute myocardial infarction-

case report.” Heart, 85(6), pp. E10.

Rambousek, L., Palenicek, T., Vales, K., Stuchlik, A. (2014). “The effect of psilocin on

memory acquisition, retrieval, and consolidation in the rat”. Frontiers in Behavioral

Neuroscience, 8. Doi: 10.3389/fnbeh.2014.00180.

Reko, B.P. (1945). Mitobotánica Zapoteca. Tacubaya, DF., Private ed.

Safford, W.E.(1916). “Edible plans and textiles of Ancient America.” Journal of Heredity,

3.

72

Sahagún, Bernardino de (1979). Historia general de las cosas de Nueva España: Codice

Florentino. México, Secretaria de Gobernación.

Sakashita, Y., Abe, K., Katagiri, N., Kambe, T., Saitoh, T., Utsunomiya, I., Horiguchi, Y.,

Taguchi, K. (2015). “Effect of Psilocin on Extracellular Dopamine and Serotonin

Levels in the Mesoaccumbens and Mesocortical Pathway in Awake Rats”. Biological

Pharmacology Bulletin, 38(1), pp. 134-138.

Saxena, P., Bolt, G., Dhasmana, K. (1987). “Serotonin agonist and antagonist in experimental

hypertension.” Journal of Cardiovascular Pharmacology, 10 (suppl. 3), pp. S12-S18.

Schmidt, A., Kometer, M., Bachman, R., Seifritz, E., Vollenweider, F. (2013). “The NMDA

antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on

structural encoding of emotional face expressions”. Psychopharmacology, 225, pp.

227-239. Doi: 10.1007/s00213-012-2811-0.

Schultes, R.E. (1972). “Hallucinogens in the Western Hemisphere.” In Furst, P. (ed.). Flesh

of the gods: The ritual use of hallucinogens. Nueva York, Praeger Publs., pp. 3-54.

Schultes, R.E., Bright, A. (1979). “Ancient gold pectoral from Colombia: mushroom

effigiers?” Bot. Mus. Leafl. Harvard Univ., 27, pp. 113-141.

Schultes, R.E., Hofman, A. (2015). Plantas de los dioses. Orígenes del uso de los alucígenos.

México, Fondo de Cultura Económica.

Schultes, R.E. (1982). Plantas alucinógenas. México, La Prensa Médica Mexicana, S.A.

Seeman, P. (2006). “Targeting the dopamine D2 receptor in schizophrenia.” Expert Opin

Ther Targets, 10, pp. 515-531.

73

Shepard G.H. Jr., Arora, D., Lampman, A. (2008). “The Grace of the Flood: Classification

and Use of Wild Mushrooms among the Highland Maya of Chiapas”. Economic

Botany, 62(3), pp. 437-470.

Sibley, D.R. (1999). “New insights into dopaminergic receptor function using entisense and

genetically altered animals.” Annu Rev Pharmacol Toxicol, 39, pp. 313-341.

Sibley, D.R., Monsma, F.J., Jr. (1992).”Molecular biology of dopamine receptors.” Trends

Pharmacol Sci, 13, pp. 61-69.

Singer, R., Smith, A.H. (1958). “Mycological investigations on Teonacátl, the Mexican

hallucinogenic mushroom II. A taxonomic monograph of Psilocybe, section

Caerulescentes.” Mycología, 50, pp. 262-303.

Singer, T., Kiebel, S.J., Winston, J.S., Dolan, R.J., Frith, C.D. (2004). “Brain responses to

the acquired moral status of faces.” Neuron, 41, pp. 653-662.

Snyder, S.H., Taylor, K.M., Coyle, J.T., Meyerhoff, J.L. (1970). “The role of brain dopamine

in behavioral regulation and the actions of psychotropic drugs.” Am J Psychiatry, 127,

pp. 199-207.

Sokoloff, P., Andrieux, M., Besancon, R., Pilon, C., Martres, M.P., Giros, B., Schwartz, J.C.

(1992). “Pharamcology of human dopamine D3 receptor expressed in a mammalian

cell line: comparison with D2 receptor.” Eur J Pharmacol, 225, pp. 331-337.

Stamets, P. (1996). Psilocybin mushrooms of the world. Berkeley, Ten Speed Press.

Stephenson, S.L. (2010). The Kingdon Fungi. The Biology of Mushrooms, Molds, and

Lichens. Portland, Londres, Timber Press.

74

Tian, T., Qin, W., Liu, B., Jiang, T., Yu, C. (2013). “Functional connectivity in healthy

subjects is nonlinearly modulated by the COMT and DRD2 polymorphisms in a

functional system-dependent manner.” J Neurosci, 33, pp.17519-17526.

Toby Evans, S. (2008). Ancient Mexico and Central America. Archaeology and Culture

History. Londres, Thames and Hudson.

Torres, G., Gainetdinov, R., Caron, M. (2003). “Plasma membrane monoamine transporters:

structure, regulation and function.” Neuroscience, 4, pp. 12-26.

Tyls, F., Palenicek, T., Horacek, J. (2013). “Psolicybin-summary of knowledge and new

perspectives.” Eur. Neuropsychopharmacol., 24, pp. 342-356. Doi:

10.1016/j.euroneuro.2013.12.006.

Underwood, M.D., Mann, J.J., Huang, Y.Y. et al. (2008). “Family history of alcoholism is

associated with lower 5-HT2A receptor binding in the prefrontal cortex.” Alcohol

Clin Exp Res, 32, pp. 593-599.

Vanhoutte, P. (1987). “cardiovascular effects of serotonin.” Journal of Cardiovascular

Pharmacology, 10 (suppl. 3), S8-S11.

Wasson, R.G. (1980). El hongo maravilloso: Teonanácatl. Micolatría en Mesoamérica.

México, Fondo de Cultura Económica.

Williams, A.R. (2012). “Los señores Dorados de Panamá (El Dorado de Panamá). Las

tumbas de los antiguos jefes de Centro América.” Natural Geographic Magazine,

enero, pp. 66-81.

75

Yamaguchi, M., Saito, T., Horiguchi, Y., Ogawa, K., Tsugiya, Y., Hishinuma, K., Chikuma,

T., Makino, Y., Hojo, H. (2004). “Preparation of Monoclonal Antibodies Reactive to

a Hallucinogenic Drug, Psilocin”. Journal of Health Service, 50(6), pp. 600-604.

Zhuk, O., Jasicka-Misiak, I., Poliwoda, A., Kazakova, A., Godovan, V.V., Halama, M.,

Wieczorek, P.P. (2015). “Research on Acute Toxicity and the Behavioral Effects of

Methanilic Extract from Psilocybin Mushrooms and Psilocin”. Toxins, 7, pp. 1018-1029.

Doi: 10.3390/toxins7041018.